

Rhodes Jason P
Form 3
May 30, 2013

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Rhodes Jason P

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

05/30/2013

3. Issuer Name **and** Ticker or Trading Symbol
Epizyme, Inc. [EPZM]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

___ Director ___X___ 10% Owner

___X___ Officer ___ Other
(give title below) (specify below)

EVP, CFO and Treasurer

6. Individual or Joint/Group
Filing(Check Applicable Line)
___X___ Form filed by One Reporting
Person
___ Form filed by More than One
Reporting Person

C/O EPIZYME, INC.,Â 400
TECHNOLOGY SQUARE

(Street)

CAMBRIDGE,Â MAÂ 02139

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

Date Expiration
Exercisable Date

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title Amount or
Number of
Shares

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)
or Indirect
(I)

6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

| | | | | | | | |
|-----------------------------|--------------|------------|--------------|--------------------|--------------------|---|---|
| Stock Option (right to buy) | Â <u>(1)</u> | 03/17/2020 | Common Stock | 326,459 <u>(2)</u> | \$ 0.51 <u>(2)</u> | D | Â |
| Stock Option (right to buy) | Â <u>(3)</u> | 03/10/2021 | Common Stock | 108,819 <u>(2)</u> | \$ 0.6 <u>(2)</u> | D | Â |
| Stock Option (right to buy) | Â <u>(4)</u> | 01/24/2023 | Common Stock | 310,833 <u>(2)</u> | \$ 3.54 <u>(2)</u> | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|--------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Rhodes Jason P C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139 | â | â X | â EVP, CFO and Treasurer | â |

Signatures

/s/ Stephen Garbacz,
attorney-in-fact

05/30/2013

**Signature of Reporting Person

Date _____

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on March 18, 2010 with respect to 326,459 shares of Common Stock, with 25% vesting on March 12, 2011 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- (2) Reflects a one-for-three reverse stock split effected on May 13, 2013.
- (3) This option was granted on March 11, 2011 with respect to 108,819 shares of Common Stock, with 25% vesting on March 11, 2012 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
- (4) This option was granted on January 25, 2013 with respect to 310,833 shares of Common Stock, with 25% vesting on January 25, 2014 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.